ONC · NASDAQ · STOCK
BeOne Medicines (ONC) Stock Analysis
$372.46
52W $253.95 – $385.22
64/100
$37.30B
24.0
0.52
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is ONC Bullish or Bearish?
Bullish.
Innellis AI committee rates BeOne Medicines AG (ONC) Buy with a composite score of 64/100
, based on 6 analysts with 67% agreement.
Last updated October 14, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.03 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.97 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 31.1% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2802.55). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 31.1% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.40 across 5 articles, 14d) — News
Bear Case
- P/E of 62.2 is expensive by classic value standards — Value
- Price-to-book of 8.7x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 14, 2026
Overall Committee Score
64/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 9%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 62.2 is expensive by classic value standards
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 31.1% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
70
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 5 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2802.55)
Investment Thesis Evolution
Committee score moved marginally from 66.5 to 64.0.
- New bearish signals: 2 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Macro Analyst: score 80->65 (-15).
- Portfolio Manager: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-13 to 2026-10-14 (1 day apart).
Technical Analysis
RSI (14)
40.7
Neutral
MACD Histogram
-1.771
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$340.00
Resistance
$355.04
Bollinger %B
0.20
Inside Bands
Price vs Moving Averages
EMA 9
$354.69
Above
EMA 21
$356.74
Above
EMA 50
$350.95
Above
EMA 200
$325.12
Above
Fundamental Analysis
Valuation
55
Growth
75
Profitability
55
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
24.0×
P/B Ratio
10.05×
PEG Ratio
-0.39
Dividend Yield
0.00%
52W High
$385.22
52W Low
$253.95
Quality & Growth
ROE
657.9%
ROA
350.4%
Gross Margin
8781.7%
Operating Margin
1505.4%
Revenue Growth YoY
—
Debt / Equity
0.22
AI Fundamental Assessment
P/E ratio of 24.0 (inexpensive relative to a 15-40x range); Price-to-book of 10.1x; PEG ratio of -0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 6.6%; Return on assets of 3.5%; Net margin of 10.7%; Gross margin of 87.8%; Current ratio of 3.40 (healthy short-term liquidity); Debt-to-equity of 0.22; Free cash flow per share is positive (11.81); EPS growth accelerating (+267.1% -> +1231.8% QoQ); Analyst estimates falling over recent quarters
Get the Full ONC Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →